{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-088365","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2026-08-12T20:14:11+00:00","discovered_at":"2026-08-12T20:15:04.439411+00:00","generated_at":"2026-08-12T20:15:12.480647+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Longeveron Q2 net loss widens to $6.1M; cash $10.1M into Q4 2026; ELPIS II top-line Sept","bullets":["Revenue flat at $0.3M; gross profit up 25% to ~$0.2M; G&A up 23% to $3.2M; R&D up 7% to $3.2M.","Net loss $6.1M vs $5.0M YoY; cash $10.1M expected to fund into Q4 2026; seeks additional financing.","ELPIS II Phase 2b top-line results for laromestrocel in HLHS expected September 2026; DMC no safety concerns.","Selected as XPRIZE Healthspan Finalist; receives $1.0M Milestone 2 Award; eligible for up to $81M Grand Prize.","Three new independent directors added to board; EMA SME status granted in June."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-088365","json":"https://secwatch.observer/filing/0001213900-26-088365.json","markdown":"https://secwatch.observer/filing/0001213900-26-088365.md","text":"https://secwatch.observer/filing/0001213900-26-088365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/0001213900-26-088365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/ea0301757-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:15:12.480647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}